



*ABOS Musculoskeletal  
Oncology Practice-Profiled  
Recertification Examination  
Blueprint*

*[www.abos.org](http://www.abos.org)*

# ABOS Musculoskeletal Oncology Practice-Profiled Recertification Examination Blueprint

## Table of Contents

---

<b>General Principles</b>	<b>3-8%</b>
<i>Biostatistics/Epidemiology</i>	1-3%
<i>Legal/Ethical/Systems-based Practice</i>	1-3%
<i>Basic Science Principles</i>	1-3%
<i>Anatomy and Surgical Approaches</i>	4-6%
<i>Perioperative Management</i>	1-3%
<b>Neoplasms</b>	<b>79-95%</b>
<i>Malignant Bone</i>	22-24%
<i>Benign Bone</i>	14-16%
<i>Metastatic Disease</i>	14-16%
<i>Myeloma, Lymphoma</i>	5-7%
<i>Benign Soft Tissue</i>	6-8%
<i>Pseudotumors/Imposters/Other</i>	3-5%
<i>Malignant Soft Tissue Tumor</i>	14-16%
<i>Syndromes</i>	1-3%

# ABOS Musculoskeletal Oncology Practice-Profiled Recertification Examination Blueprint

<b>General Principles</b>	<b>8-18%</b>
<b>Biostatistics/Epidemiology</b>	<b>1-3%</b>
<ul style="list-style-type: none"><li>• Interpretation of epidemiologic information [Disease prevalence and incidence, disease outcomes (eg, fatality rates), associations (eg, risk factors), health impact (eg, risk differences and ratios), sensitivity, specificity, predictive values]</li><li>• Study design and interpretation [Types of experimental studies (eg, clinical trials), types of observational studies (eg, cohort, case-control), sampling and sample size, subject selection and exposure allocation (eg, randomization)]</li><li>• Hypothesis testing and statistical interference [Confidence intervals, statistical significance and type I error, statistical power and type II error]</li></ul>	
<b>Legal/Ethical/Systems-based Practice</b>	<b>1-3%</b>
<ul style="list-style-type: none"><li>• Consent and informed consent to treatment, physician-patient relationship, death and dying, research issues, diversity, interactions with other health professionals, cultural competence, physician wellness/burnout, safety, quality, teamwork, cost, value-based care</li></ul>	
<b>Basic Science Principles</b>	<b>1-3%</b>
<ul style="list-style-type: none"><li>• Biology (fracture healing, biologics, pharmacology), biomechanics (including gait), inflammatory cascades and coagulation</li></ul>	
<b>Anatomy and Surgical Approaches</b>	<b>4-6%</b>
<ul style="list-style-type: none"><li>• Anatomy, surgical approaches, and soft-tissue coverage</li></ul>	
<b>Perioperative Management</b>	<b>1-3%</b>
<ul style="list-style-type: none"><li>• Preoperative (infection and medical optimization, including nutrition, smoking cessation, glucose management/diabetes, weight loss, prehabilitation, inflammatory arthritis evaluation and management)</li><li>• Intraoperative (anesthesia/blocks, blood loss prevention, infection prevention, wound management, complications and safety)</li><li>• Postoperative (multimodal pain management, rehabilitation, wound management, blood management, discharge disposition, prosthetics, deep vein thrombosis, pulmonary embolism, delirium, coagulopathy, surveillance)</li></ul>	

<b>Neoplasms</b>	<b>79-95%</b>
<b>Malignant Bone</b>	<b>22-24%</b>
<ul style="list-style-type: none"> <li>• Imaging, staging, biopsy, systemic therapy, local therapy, osteosarcoma, chondrosarcoma, Ewing sarcoma, chordoma, adamantinoma, management of unplanned excisions</li> </ul>	
<b>Benign Bone</b>	<b>14-16%</b>
<ul style="list-style-type: none"> <li>• Imaging, biopsy, operative and nonoperative treatment, nonossifying fibromas, cysts, giant cell tumors, osteoid osteoma, osteoblastoma, metabolic bone disease, Langerhans cell histiocytosis, enchondroma</li> </ul>	
<b>Metastatic Disease</b>	<b>14-16%</b>
<ul style="list-style-type: none"> <li>• Pathologic fractures, prophylactic fixation, nonoperative spine*, radiation, bisphosphonates, Denosumab, imaging, evaluation, biopsy</li> </ul>	
<b>Myeloma, Lymphoma</b>	<b>5-7%</b>
<ul style="list-style-type: none"> <li>• Pathologic fractures, prophylactic fixation, nonoperative spine, radiation, bisphosphonates, Denosumab, imaging, evaluation, biopsy</li> </ul>	
<b>Benign Soft Tissue</b>	<b>6-8%</b>
<ul style="list-style-type: none"> <li>• Imaging, biopsy, pigmented villonodular synovitis, arteriovenous malformation, myositis, myxoma, lipoma, nerve sheath tumors, fibromatosis</li> </ul>	
<b>Pseudotumors/Imposters/Other</b>	<b>3-5%</b>
<b>Malignant Soft Tissue Tumor</b>	<b>14-16%</b>
<ul style="list-style-type: none"> <li>• Imaging, biopsy, staging, operative treatment, radiation, sarcoma, chemotherapy/targeted therapy, management of unplanned excisions</li> </ul>	
<b>Syndromes</b>	<b>1-3%</b>
<ul style="list-style-type: none"> <li>• Li Fraumeni, multiple hereditary exostoses, Ollier disease, Maffucci syndrome, McCune-Albright syndrome, neurofibromatosis</li> </ul>	

\*no more than 1 spine item